Take a trial of UK to unlock this pageFind out more

Avacta

AVCT 80p 0.0  0.0%
05/12/16 1.50k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Jul 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -5.2%

FINANCIAL BRIEF: For the fiscal year ended 31 July 2016, Avacta Group Plc revenues increased 19% to L2.2M. Net loss before extraordinary items decreased 5% to L4.6M. Revenues reflect Life Sciences segment increase of 60% to L704K, Animal Health segment increase of 6% to L1.5M. Lower net loss reflects Unallocated segment loss decrease of 60% to L1.7M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.10 to -L0.07. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
E+
E+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Jul '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Jul 2017
31st Jul 2018

Price Target: 1.80
(+1251% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
3 brokers Broker Consensus Trend
Broker Recommendations for Avacta
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 2

Named Brokers and Analysts
Panmure Gordon , Hardman & Company Martin Hall , Numis Securities Sally Taylor , Edison Investment Research , FinnCap Mark Brewer , Hume Capital Timothy Freeborn ,

Profile Summary

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company's segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company's in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.

Directors: Alastair Smith (CEO) , Tony Gardiner (CFO) 44, Craig Slater (COO) , Trevor Nicholls (NEC) 58, Michael Albin (NED) , Gwyn Humphreys (NED) , Michael Owen (NED) 64, Alan Aubrey (NID) 54,

No. of Employees: 87 No. of Shareholders: n/a


Last Annual July 31st, 2016
Last Interim July 31st, 2016
Incorporated April 29, 2003
Public Since September 8, 2003
Shares in Issue 68,382,517
Free Float 46.6m (68.2%)
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

AVCT Share Price Performance AVCTQuote
0.0  0.0%
Traded 2:51pm · Minimum 15 min delayed · NMS: 1.50k

Latest AVCT News Announcements (delayed)

Upcoming AVCT Events
Monday 24th April, 2017 (estimate)
Half Year 2017 Avacta Group PLC Earnings Release

Recent ↓
Monday 17th October, 2016
Full Year 2016 Avacta Group PLC Earnings Release
Thursday 23rd June, 2016
Avacta Group PLC at Berenberg Discovery Conference
Monday 25th April, 2016
Half Year 2016 Avacta Group PLC Earnings Release
Tuesday 26th January, 2016
Avacta Group PLC Reverse Split For AVCT.L
Wednesday 15th July, 2015
Avacta Group PLC Secondary Public Offering Filing


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.


Should you buy AVCT

Access AVCT Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder